1. China's CDE sets out how trial safety information should flow between sponsors, investigators and ethics committees

China's Center for Drug Evaluation (CDE) has published a technical guideline on safety information reporting and risk communication in drug clinical trials (Notice No. 52 of 2026), effective on publication. It applies a "risk-proportionate" principle: individual SUSARs that could change the protocol, investigator's brochure or informed consent, or pause or stop the trial, should be expedited to investigators and ethics committees, while other individual SUSARs can go in a monthly report with an overall safety assessment and line listing. Timelines follow ICH E2A (24 hours for immediate reports; 7 days for fatal or life-threatening and 15 days for other expedited reports), other potentially serious safety information must be reported within 15 days of being identified as such, and investigators and ethics committees should receive the DSUR executive summary and serious adverse reaction line listing within two months of the development international birth date. Sponsors running trials in China should check that their SUSAR distribution rules and ethics committee submissions match this model. CDE Notice No. 52/2026, published 9 Nov 2026

2. Health Canada finds a possible link between entrectinib (Rozlytrek) and myocarditis

A Health Canada summary safety review, triggered by the manufacturer's notice of a labelling update in another country, found a possible link between entrectinib and myocarditis. Health Canada assessed 7 international cases, all hospitalised and all possibly linked to entrectinib, including one death; the 2 Canadian reports received were not confirmed as myocarditis. The Canadian product monograph will be updated and healthcare professionals informed through Health Product InfoWatch. The case is a reminder that a foreign labelling action is itself a trigger for safety reviews elsewhere, and that marketing authorisation holders need consistent cardiac safety wording across regions for kinase inhibitors with small exposed populations (about 115 patients in Canada from 2020 to 2025). Health Canada summary safety review, Nov 2026

3. Australia: more andrographis medicines recalled after a sustained anaphylaxis signal

The TGA's recall database lists a Class I consumer-level recall of all in-date batches of JSHealth Vitamins Immune+ tablets, starting 6 November, adding to more than 30 andrographis-containing listed medicines recalled since October. Despite a mandatory allergy warning since 2019, the TGA kept receiving a high number of anaphylaxis reports, including a fatal case reported in June 2024, and concluded that the risk could not be managed within the low-risk listed medicines framework; andrographis has been removed from the permitted ingredients list. For safety teams, it is an example of label warnings failing as a risk minimisation measure, and of a regulator moving from labelling to removing an ingredient altogether. TGA recall RC-2026-RN-00900-1, 6 Nov 2026 · TGA andrographis recalls, updated 30 Oct 2026


This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.

Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles